| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Hsp90 (Heat Shock Protein 90) and ABCG2 (Breast Cancer Resistance Protein). Falcarinol is an Hsp90 inhibitor that binds to both the N- and C-terminal ATP-binding sites of Hsp90. It also inhibits the drug efflux transporter ABCG2 with an IC50 of 79.3 uM, potentially impacting multidrug resistance.
|
|---|---|
| ln Vitro |
By triggering apoptosis, panaxynol prevents NSCLC CSCs from forming spheres. With no effect on normal cells, panaxynol reduces the viability of NSCLC cells[1].
In vitro, Falcarinol inhibits Hsp90 ATPase activity and induces apoptosis in non-small cell lung cancer (NSCLC) cells while having no effect on normal cells. It prevents the formation of cancer stem cell (CSC) spheres. In Caco-2 colorectal cancer cells, treatment (0.001-20 ug/mL, 72h) significantly reduces cell proliferation. It also inhibits the fatty acid biosynthesis pathway, contributing to antimicrobial properties. |
| ln Vivo |
In vivo, Falcarinol is orally bioactive, supporting its potential as a dietary chemopreventive agent. It has primarily been used in inflammatory models and colorectal cancer prevention research. By inhibiting Hsp90 and inducing apoptosis, oral administration may reduce tumor burden in preclinical cancer models, though specific xenograft studies are more commonly reported for other polyacetylenes rather than this specific compound.
|
| Enzyme Assay |
For Hsp90 ATPase inhibition assays, purified recombinant Hsp90 is incubated with malachite green reagent. Falcarinol is added at varying concentrations (0.1-100 uM). The reaction is initiated by adding ATP. The release of free phosphate is measured by the increase in absorbance at 620 nm. For ABCG2 inhibition, membrane vesicles containing ABCG2 are incubated with [3H]-methotrexate and varying concentrations of Falcarinol.
|
| Cell Assay |
For anti-proliferation assays, Caco-2 colorectal adenocarcinoma cells are seeded in 96-well plates and treated with Falcarinol (0.1-50 uM) for 24-72 hours. Cell viability is assessed by MTT or CellTiter-Glo assay. For apoptosis detection, treated cells are stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. Cancer stem cell sphere formation assays are conducted in low-attachment plates.
|
| Animal Protocol |
For preclinical in vivo studies, Falcarinol is typically administered orally to mouse models of colorectal cancer or colitis. Doses are based on previous bioavailability studies. Tumor incidence and multiplicity are measured in carcinogen-induced models. For pharmacodynamic assessment, colon tissues are collected for Hsp90 client protein analysis (e.g., HIF-1alpha, AKT, HER2) by Western blot and for proliferation markers (Ki-67) by immunohistochemistry to confirm target engagement.
|
| ADME/Pharmacokinetics |
Falcarinol is orally absorbed and has a molecular weight of 244.33 g/mol. In vivo studies show that it distributes to target tissues and is cleared over time. Detailed pharmacokinetic parameters such as half-life (t1/2), Cmax, and AUC are not as extensively documented for this natural product as for synthetic drugs. It is often formulated in aqueous buffers with a carrier such as cyclodextrin to enhance solubility.
|
| Toxicity/Toxicokinetics |
Falcarinol is a natural product with reported limited toxicity, even at doses that are effective in vivo. Unlike many standard Hsp90 inhibitors that target only the N-terminal ATP pocket (which can cause severe dose-limiting toxicities), Falcarinol's dual N- and C-terminal binding mechanism may contribute to a more favorable safety profile. However, it is classified as a potential contact allergen and can cause dermatitis (carrot dermatitis) in humans. Use caution when handling.
|
| References | |
| Additional Infomation |
Ginsenoside is a long-chain fatty alcohol with the effects of metabolites. It has been reported that facalool is present in Acanthopanax senticosus, Angelica sinensis, and other organisms with relevant data. Mechanism of Action: We tested the effects of ethanol extracts from 10 traditional Chinese medicinal herbs on the proliferation of K562, Raji, Wish, HeLa, Calu-1, and Vero tumor cells. The results showed that ginsenoside purified from Saposhnikovae divaricata exhibited the highest inhibitory activity against the proliferation of various tumor cells. Cell cycle analysis indicated that ginsenoside can arrest the cell cycle progression of tumor cells, causing them to transition from G1 phase to S phase. To further determine the cell cycle node at which arrest occurs, we examined the gene expression of cyclin E, a key regulator at the G1/S phase junction. The results showed that ginsenoside can reduce the level of cyclin E mRNA in various tumor cells. Therefore, the inhibitory effect of ginsenosides on the proliferation of various tumor cells is at least partly achieved by reducing the level of cyclin E mRNA and arresting the cell cycle.
Falcarinol is a naturally occurring pesticide and phytochemical found in carrots and other vegetables. It is not an FDA-approved drug. It is undergoing research for colorectal cancer chemoprevention due to its Hsp90 inhibition and induction of apoptosis. Its presence in the diet has been associated with beneficial health effects, but it also acts as an allergen. It is a research-grade compound for in vitro and preclinical studies only. |
| Molecular Formula |
C17H24O
|
|---|---|
| Molecular Weight |
244.37
|
| Exact Mass |
244.182
|
| CAS # |
21852-80-2
|
| PubChem CID |
5281149
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
370.6±42.0 °C at 760 mmHg
|
| Flash Point |
163.4±20.9 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.507
|
| LogP |
6.96
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
18
|
| Complexity |
363
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(OP(OC1CC(N2C(=O)N=C(N)C=C2)OC1COP(OC1CC(N2C(=O)N=C(N)C=C2)OC1COP(OC1CC(N2C(=O)N=C(N)C=C2)OC1COP(OC1CC(N2C=CC(N)=NC2=O)OC1CO)(O)=S)(O)=S)(O)=S)(O)=S)C1OC(N2C(=O)N=C(N)C=C2)CC1OP(OCC1C(O)CC(N2C=CC(N)=NC2=O)O1)(=O)S
|
| InChi Key |
UGJAEDFOKNAMQD-QXPKXGMISA-N
|
| InChi Code |
InChI=1S/C17H24O/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17(18)4-2/h4,10-11,17-18H,2-3,5-9,12H2,1H3/b11-10-/t17-/m1/s1
|
| Chemical Name |
(3R,9Z)-heptadeca-1,9-dien-4,6-diyn-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0922 mL | 20.4608 mL | 40.9216 mL | |
| 5 mM | 0.8184 mL | 4.0922 mL | 8.1843 mL | |
| 10 mM | 0.4092 mL | 2.0461 mL | 4.0922 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
